keine Finanzberatung

RVTY · Revvity

Life-science tools and diagnostics maker, the former PerkinElmer

Risiko 4/10 · MODERATE RISK · life-science tools spin-off · $130.22 ▼ 0.31%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $130.22
  • Market cap $14.5B
  • P/E (ttm) 62.61
  • Div yield 0.22%
  • 52-wk range $81.22 – $133.00
  • Index rank #467 / —

Wichtigste Risiken

  • Prolonged biotech-funding slump curbs instrument demand (Shareholders) — MED
  • China diagnostics exposure and reimbursement pressure (Shareholders) — MED
  • Multiple compression if growth stays near zero (Shareholders) — MED
  • New-product launches (prenatal screening) underdelivering (Shareholders) — LOW

Fazit

Solid, slow, and fully priced — a defensive tools name that needs growth to return before the stock does much.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.